Cargando…
Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy
PURPOSE: SMT C1100 is a utrophin modulator being evaluated as a treatment for Duchenne muscular dystrophy (DMD). This study, the first in pediatric DMD patients, reports the safety, tolerability and PK parameters of single and multiple doses of SMT C1100, as well as analyze potential biomarkers of m...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824384/ https://www.ncbi.nlm.nih.gov/pubmed/27055247 http://dx.doi.org/10.1371/journal.pone.0152840 |
_version_ | 1782426079142608896 |
---|---|
author | Ricotti, Valeria Spinty, Stefan Roper, Helen Hughes, Imelda Tejura, Bina Robinson, Neil Layton, Gary Davies, Kay Muntoni, Francesco Tinsley, Jonathon |
author_facet | Ricotti, Valeria Spinty, Stefan Roper, Helen Hughes, Imelda Tejura, Bina Robinson, Neil Layton, Gary Davies, Kay Muntoni, Francesco Tinsley, Jonathon |
author_sort | Ricotti, Valeria |
collection | PubMed |
description | PURPOSE: SMT C1100 is a utrophin modulator being evaluated as a treatment for Duchenne muscular dystrophy (DMD). This study, the first in pediatric DMD patients, reports the safety, tolerability and PK parameters of single and multiple doses of SMT C1100, as well as analyze potential biomarkers of muscle damage. METHODS: This multicenter, Phase 1 study enrolled 12 patients, divided equally into three groups (A–C). Group A were given 50 mg/kg on Days 1 and 11, and 50 mg/kg bid on Days 2 to 10. Group B and C received 100 mg/kg on Days 1 and 11; Group B and Group C were given 100 mg/kg bid and 100 mg/kg tid, respectively, on Days 2 to 10. A safety review was performed on all patients following the single dose and there was at least 2 weeks between each dose escalation, for safety and PK review. Adverse events (AEs) were monitored throughout the study. RESULTS: Most patients experienced mild AEs and there were no serious AEs. Two patients required analgesia for pain (headache, ear pain and toothache). One patient experienced moderate psychiatric AEs (abnormal behaviour and mood swings). Plasma concentrations of SMT C1100 at Days 1 and 11 indicated a high degree of patient variability regardless of dose. Unexpectedly the SMT C1100 levels were significantly lower than similar doses administered to healthy volunteers in an earlier clinical study. In general, individual baseline changes of creatine phosphokinase, alanine aminotransferase, aspartate aminotransferase levels fell with SMT C1100 dosing. CONCLUSIONS: SMT C1100 was well tolerated in pediatric DMD patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT02383511 |
format | Online Article Text |
id | pubmed-4824384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-48243842016-04-22 Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy Ricotti, Valeria Spinty, Stefan Roper, Helen Hughes, Imelda Tejura, Bina Robinson, Neil Layton, Gary Davies, Kay Muntoni, Francesco Tinsley, Jonathon PLoS One Research Article PURPOSE: SMT C1100 is a utrophin modulator being evaluated as a treatment for Duchenne muscular dystrophy (DMD). This study, the first in pediatric DMD patients, reports the safety, tolerability and PK parameters of single and multiple doses of SMT C1100, as well as analyze potential biomarkers of muscle damage. METHODS: This multicenter, Phase 1 study enrolled 12 patients, divided equally into three groups (A–C). Group A were given 50 mg/kg on Days 1 and 11, and 50 mg/kg bid on Days 2 to 10. Group B and C received 100 mg/kg on Days 1 and 11; Group B and Group C were given 100 mg/kg bid and 100 mg/kg tid, respectively, on Days 2 to 10. A safety review was performed on all patients following the single dose and there was at least 2 weeks between each dose escalation, for safety and PK review. Adverse events (AEs) were monitored throughout the study. RESULTS: Most patients experienced mild AEs and there were no serious AEs. Two patients required analgesia for pain (headache, ear pain and toothache). One patient experienced moderate psychiatric AEs (abnormal behaviour and mood swings). Plasma concentrations of SMT C1100 at Days 1 and 11 indicated a high degree of patient variability regardless of dose. Unexpectedly the SMT C1100 levels were significantly lower than similar doses administered to healthy volunteers in an earlier clinical study. In general, individual baseline changes of creatine phosphokinase, alanine aminotransferase, aspartate aminotransferase levels fell with SMT C1100 dosing. CONCLUSIONS: SMT C1100 was well tolerated in pediatric DMD patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT02383511 Public Library of Science 2016-04-07 /pmc/articles/PMC4824384/ /pubmed/27055247 http://dx.doi.org/10.1371/journal.pone.0152840 Text en © 2016 Ricotti et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Ricotti, Valeria Spinty, Stefan Roper, Helen Hughes, Imelda Tejura, Bina Robinson, Neil Layton, Gary Davies, Kay Muntoni, Francesco Tinsley, Jonathon Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy |
title | Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy |
title_full | Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy |
title_fullStr | Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy |
title_full_unstemmed | Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy |
title_short | Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy |
title_sort | safety, tolerability, and pharmacokinetics of smt c1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to pediatric patients with duchenne muscular dystrophy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824384/ https://www.ncbi.nlm.nih.gov/pubmed/27055247 http://dx.doi.org/10.1371/journal.pone.0152840 |
work_keys_str_mv | AT ricottivaleria safetytolerabilityandpharmacokineticsofsmtc1100a2arylbenzoxazoleutrophinmodulatorfollowingsingleandmultipledoseadministrationtopediatricpatientswithduchennemusculardystrophy AT spintystefan safetytolerabilityandpharmacokineticsofsmtc1100a2arylbenzoxazoleutrophinmodulatorfollowingsingleandmultipledoseadministrationtopediatricpatientswithduchennemusculardystrophy AT roperhelen safetytolerabilityandpharmacokineticsofsmtc1100a2arylbenzoxazoleutrophinmodulatorfollowingsingleandmultipledoseadministrationtopediatricpatientswithduchennemusculardystrophy AT hughesimelda safetytolerabilityandpharmacokineticsofsmtc1100a2arylbenzoxazoleutrophinmodulatorfollowingsingleandmultipledoseadministrationtopediatricpatientswithduchennemusculardystrophy AT tejurabina safetytolerabilityandpharmacokineticsofsmtc1100a2arylbenzoxazoleutrophinmodulatorfollowingsingleandmultipledoseadministrationtopediatricpatientswithduchennemusculardystrophy AT robinsonneil safetytolerabilityandpharmacokineticsofsmtc1100a2arylbenzoxazoleutrophinmodulatorfollowingsingleandmultipledoseadministrationtopediatricpatientswithduchennemusculardystrophy AT laytongary safetytolerabilityandpharmacokineticsofsmtc1100a2arylbenzoxazoleutrophinmodulatorfollowingsingleandmultipledoseadministrationtopediatricpatientswithduchennemusculardystrophy AT davieskay safetytolerabilityandpharmacokineticsofsmtc1100a2arylbenzoxazoleutrophinmodulatorfollowingsingleandmultipledoseadministrationtopediatricpatientswithduchennemusculardystrophy AT muntonifrancesco safetytolerabilityandpharmacokineticsofsmtc1100a2arylbenzoxazoleutrophinmodulatorfollowingsingleandmultipledoseadministrationtopediatricpatientswithduchennemusculardystrophy AT tinsleyjonathon safetytolerabilityandpharmacokineticsofsmtc1100a2arylbenzoxazoleutrophinmodulatorfollowingsingleandmultipledoseadministrationtopediatricpatientswithduchennemusculardystrophy |